Apyx Medical Corp. (APYX) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apyx Medical Corporation Reports Third Quarter 2020 Financial Results
November 9, 2020 7:00 AM ESTCLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its third quarter ended September 30, 2020.
Third Quarter 2020 Financial Summary:
Total revenue of $7.0 million, down 8.2% year-over-year. Advanced Energy revenue of $5.5 million, down 10.1% year-over-year. OEM revenue of $1.5 million, down 0.4%... More